Home › Insulin Resistance › NCT07780513
Genetic of Skeletal Muscle Insulin Resistance
Identification of Cell Type-Specific Insulin Responsive Quantitative Trait Loci (QTL) in Human Skeletal Muscle
Who can join
Ages 18 to 75 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Males and Females Age 18-75 * Body Mass Index (BMI) \> 18 * Normal glucose tolerance as defined by: Fasting blood sugar \< 100 mg/dL 2-hour Oral Glucose Tolerance Test (OGTT) \< 140mg/dL Stable weight over the past 3 months defined as \>±5% change in body weight * Hemoglobin A1c \< 5.7 * Creatinine \< 2 * Aspartate aminotransferase/Alanine transaminase (AST/ALT) \< 75 * Blood sodium 135 to 145 mEq/L * Blood potassium 3.6 to 5.2 mmol/L\[MH1.1\] Exclusion Criteria: * Urine albumin excretion\>300mg/day * Partial thromboplastin time (PTT) \>35International normalized ratio (INR) \> 1.2 * No oral corticosteroids for 1 month * No Sodium-glucose co-transporter 2 (SGLT2) inhibitor for 3 months * No glucagon-like peptide-1 (GLP-1) receptor agonist for 6 months * Any anti-platelet or anti-coagulation medication other than as needed for Pain Management * No alcohol 4 days before the insulin clamp and biopsy procedure * No acute structural knee injuries * No Rheumatologic muscular or nervous system disease * Pregnancy, Intentions to become pregnant, or Breastfeeding * Blood Pressure \>170/110 * Temperature \> 100F * Triglycerides \> 400 by lipid panel * Hemoglobin \<10g/dL * 1+ or greater Blood on Urinalysis * 2+ or greater Protein on Urinalysis * Electrocardiogram (EKG) abnormalities, including but not limited to ST elevations, T wave abnormalities, evidence of recent prior infarct
About the study
In this study, the investigators will use euglycemic/hyperinsulinemic clamps, longitudinal skeletal muscle biopsies, and single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) to reveal cell type-specific molecular response quantitative trait loci (rQTLs) acutely regulated by insulin signaling and glucose uptake.
What is being tested
- Insulin 80mU/m2*min (other)
Sponsor: The University of Texas Health Science Center at San Antonio · Participants: 100 · Started: Aug 31, 2026
Contact the study team
- Luke Norton, Ph.D · Phone: 210-567-0739
Official record on ClinicalTrials.gov — NCT07780513
Locations in the U.S.
| Texas | Texas Diabetes Institute - University Health System, San Antonio, Texas 78207, San Antonio |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.